The Research Report on Antinuclear Antibody Test Market provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the market, along with revenue estimates & forecasts and market share analysis.
The increasing prevalence of autoimmune diseases and increasing healthcare expenditure worldwide are the major factors driving the growth of this ANA testing market.
Download PDF Brochure:
Target Audience for this Report:
- ANA Testing Instrument Manufacturers and Suppliers
- Clinical Laboratories
- Hospitals
- Pharmaceutical and Biotechnology Companies
- Academic Research Institutes Related to Antinuclear Antibody Testing
key players operating in the Global Antinuclear Antibody Test Market;
The major players in this market include Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.).
Alere Inc. (U.S.) is the second-largest player in the global ANA testing market, with a share of 15.6%. Alere operates in more than 100 countries across the globe, including the U.S., Austria, Denmark, China, Brazil, Indonesia, South Africa, and Japan. The company focuses on new product launches to strengthen its portfolio in the ANA testing market.
Major Drivers Impacting the Antinuclear Antibody Test Market;
· High Incidence of Autoimmune Diseases
· Increasing Population and Growth in Healthcare Expenditure
· Growth in the Number of Individuals Covered Under Medical Insurance
Global Antinuclear Antibody Test Market Segmentation:
Based on techniques, the Antinuclear Antibody Test Market is segmented into enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and multiplex assay. The ELISA segment is expected to account for the largest share of this market due to the expanding applications of ANA in autoimmune disease testing and therapeutic drug level monitoring.
The end user segments in the market include clinical laboratories, hospitals, POLs, and other end users. The hospital's segment is expected to account for the largest share of the global ANA testing market. Growth in this segment can be attributed to the fact that most diagnostic tests are performed in hospitals or hospital-attached laboratories, primarily due to easy access to reports and smooth logistics.
Request Research Sample Pages:
Based on region, the global antinuclear antibody test market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as rising geriatric population and increasing prevalence of autoimmune diseases.
No comments:
Post a Comment